ALZN – alzamend neuro, inc. (US:NASDAQ)
Stock Stats
News
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital [Yahoo! Finance]
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital
Alzamend Neuro (NASDAQ:ALZN) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Alzamend Neuro (NASDAQ:ALZN) had its price target lowered by analysts at Ascendiant Capital Markets from $45.00 to $42.00. They now have a "buy" rating on the stock.
Form 8-K Alzamend Neuro, Inc. For: Nov 18
Form 4 Alzamend Neuro, Inc. For: Oct 23 Filed by: McGrath Lynne Fahey
Form 8-K Alzamend Neuro, Inc. For: Oct 14
Form 4 Alzamend Neuro, Inc. For: Oct 08 Filed by: AULT MILTON C III
Form 8-K Alzamend Neuro, Inc. For: Oct 09
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.